With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies
This article was originally published in Start Up
Joseph Schlessinger’s insights into receptor tyrosine kinases (RTKs) led to small-molecule treatments and huge success at Sugen and Plexxikon. Schlessinger’s latest venture, Kolltan Pharmaceuticals, had little trouble raising $75 million, but powering up a pipeline of antibodies to target novel RTKs has proven more challenging.
You may also be interested in...
Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.
Drug candidates fail at an alarming rate. For biotechs that seemingly have their entire future - and tens of millions of investor dollars - tied up in one compound or one clinical trial, failure of a lead asset can mean certain, sudden death. Meet four small companies that had another plan.
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.